“This novel testing provides insight into whether or not a patient will experience the anticipated effect of a prescribed medication or be at increased risk for additional side effects,” said Howard Appel, president of Millennium Laboratories.
The testing will help physicians determine if the dosing and selection of certain drugs — including methadone, benzodiazepines and tricyclic antidepressants — should be modified to better suit the patient’s tolerance level.
Related Articles on Pain Management:
8 New Pain Management Program Launches, Acquisitions or Developments
Iowa Patients Lack Treatment Options After Pain Clinic Shutters
New Hampshire Prescribing Fewer Painkillers for Inmates
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
